Can below-optimal omega-3 status reduce the body’s ability to turn off inflammation?

The active resolution of inflammation is a highly regulated physiological process dependent on specialized pro-resolving lipid mediators (SPMs) synthesized from the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Substrate dependency of SPM synthesis

• Precursor pool restriction: The omega-3 index directly determines the cell membrane substrate pools available for SPM synthesis. A below-optimal index limits these precursor pools, reducing enzymatic conversion via lipoxygenase (LOX) and cyclooxygenase (COX) pathways into key pathway intermediates like 18-HEPE and 17-HDHA, which are essential for generating resolvins, protectins, and maresins.
• Enzymatic competition: Low tissue levels of EPA and DHA allow arachidonic acid to dominate shared enzymatic pathways, shifting the lipid mediator profile away from resolution and toward pro-inflammatory eicosanoids.

Mechanisms of active inflammatory resolution

• Macrophage efferocytosis: SPMs act as agonists on specific G-protein coupled receptors, such as ALX/FPR2, to halt neutrophil recruitment and actively drive macrophage efferocytosis (the clearance of apoptotic cells). This clearance prevents secondary necrosis and initiates tissue repair.
• Consequences of pathway failure: Preclinical knockout models (such as Fpr2-/- and MerTK-/-) demonstrate that disrupting these receptor pathways or impairing efferocytosis prevents the termination of inflammation, resulting in apoptotic debris accumulation and chronic, persistent tissue injury.

Bottom line

• Maintaining an optimal omega-3 index is critical to secure the precursor substrate pools required for SPM synthesis, enabling the receptor-mediated macrophage efferocytosis necessary to actively turn off the inflammatory response.